Business Description
Gennex Laboratories Ltd
ISIN : INE509C01026
Total Employee Number:
115Compare
Compare
Traded in other countries / regions
531739.India IPO Date
2000-11-12Description
Gennex Laboratories Ltd is engaged in the manufacturing of bulk drugs, and intermediates, Biotech Products. Geographically, the group has a business presence in Bangladesh, Egypt, Germany, Guatemala, Iran, Israel and other countries. Its products include Guaifenesin, Methocarbamol, Fluconazole and Phenazopyridine, among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.04 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | 2.61 | |||||
Interest Coverage | 5.82 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.59 | |||||
Beneish M-Score | -1.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.2 | |||||
3-Year EBITDA Growth Rate | 23.5 | |||||
3-Year EPS without NRI Growth Rate | 35.8 | |||||
3-Year FCF Growth Rate | -35.5 | |||||
3-Year Book Growth Rate | 26.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.4 | |||||
9-Day RSI | 34.7 | |||||
14-Day RSI | 37.1 | |||||
3-1 Month Momentum % | 3.57 | |||||
6-1 Month Momentum % | -15.58 | |||||
12-1 Month Momentum % | -20.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.66 | |||||
Quick Ratio | 2.91 | |||||
Cash Ratio | 2.23 | |||||
Days Inventory | 133.27 | |||||
Days Sales Outstanding | 71.47 | |||||
Days Payable | 47.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.2 | |||||
Shareholder Yield % | -32.37 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 25.6 | |||||
Operating Margin % | 14.15 | |||||
Net Margin % | 11.43 | |||||
EBITDA Margin % | 17.59 | |||||
FCF Margin % | -43.76 | |||||
OCF Margin % | -36.85 | |||||
ROE % | 9.51 | |||||
ROA % | 6.16 | |||||
ROIC % | 10.52 | |||||
3-Year ROIIC % | 29.56 | |||||
ROC (Joel Greenblatt) % | 22.41 | |||||
ROCE % | 10.83 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.58 | |||||
PE Ratio without NRI | 11.42 | |||||
Shiller PE Ratio | 21.59 | |||||
PEG Ratio | 0.53 | |||||
PS Ratio | 1.35 | |||||
PB Ratio | 0.98 | |||||
Price-to-Tangible-Book | 1 | |||||
EV-to-EBIT | 5.36 | |||||
EV-to-EBITDA | 4.9 | |||||
EV-to-Revenue | 0.86 | |||||
EV-to-FCF | -2.03 | |||||
Price-to-GF-Value | 0.58 | |||||
Price-to-DCF (Earnings Based) | 0.48 | |||||
Price-to-Median-PS-Value | 0.92 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.46 | |||||
Price-to-Graham-Number | 0.71 | |||||
| Price-to-Net-Current-Asset-Value | 1.59 | |||||
| Price-to-Net-Cash | 6.22 | |||||
Earnings Yield (Greenblatt) % | 18.68 | |||||
FCF Yield % | -34.25 | |||||
Forward Rate of Return (Yacktman) % | 8.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gennex Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,727.41 | ||
| EPS (TTM) (₹) | 0.785 | ||
| Beta | 1.9572 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.8 | ||
| Volatility % | 82.58 | ||
| 14-Day RSI | 37.1 | ||
| 14-Day ATR (₹) | 0.537818 | ||
| 20-Day SMA (₹) | 9.6915 | ||
| 12-1 Month Momentum % | -20.04 | ||
| 52-Week Range (₹) | 7.05 - 17.25 | ||
| Shares Outstanding (Mil) | 242.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gennex Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gennex Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 10:1 Stock Split | 2009-12-14 | 2.07 (+8.50%) |
Show
Entries
Gennex Laboratories Ltd Frequently Asked Questions
What is Gennex Laboratories Ltd(BOM:531739)'s stock price today?
The current price of BOM:531739 is ₹9.08. The 52 week high of BOM:531739 is ₹17.25 and 52 week low is ₹7.05.
When is next earnings date of Gennex Laboratories Ltd(BOM:531739)?
The next earnings date of Gennex Laboratories Ltd(BOM:531739) is .
Does Gennex Laboratories Ltd(BOM:531739) pay dividends? If so, how much?
Gennex Laboratories Ltd(BOM:531739) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Gennex Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers